Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2017.10.006
Abstract: BACKGROUND To overcome the concerns associated with the use of fibrates, pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor modulator, was developed. In a previous phase 2 trial, we showed excellent efficacy and safety of… read more here.
Keywords: efficacy safety; safety; safety pemafibrate; fenofibrate ... See more keywords